Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tariff System (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Mektovi (braftovi) for the treatment of patients with lung cancer and pleural mesothelioma
- Calquence (acalabrutinib) for the treatment of patients with chronic lymphocytic leukemia
- Krazati (adagrasib) + adagrasib for the treatment of patients with lung cancer and pleural mesothelioma
- Jemperli (dostarlimab) + dostarlimab for the treatment of patients with endometrial cancer
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
